Pankreas Tümörlerinde Palyatif Tedaviler
Özet
Pankreas kanseri vakalarının %80'inde tanı ancak hastalık ileri evreye ulaştığında konulabildiği için palyatif tedaviler, hastaların yaşam kalitesini artırmak adına kritik bir öneme sahiptir. Bu sürecin temel bileşenleri sarılık, mide çıkış obstrüksiyonu (MÇO), şiddetli ağrı ve kaşeksi ile mücadeledir. Pankreas başı tümörlerinde sık görülen obstrüktif sarılık, genellikle ERCP eşliğinde stentleme (plastik veya metal) yöntemiyle tedavi edilirken, cerrahi drenaj daha uzun sağ kalım beklentisi olan hastalarda tercih edilmektedir. Duodenal invazyon sonucu gelişen MÇO durumunda, gastrojejunostomi ameliyatı altın standart kabul edilmekle birlikte, daha az invaziv bir seçenek olan endoskopik metal stentleme de uygulanabilmektedir. Hastaların büyük kısmında görülen ve yaşam kalitesini ciddi şekilde düşüren ağrıların yönetiminde basamaklı analjezik tedavisi ve çölyak sinir bloğu öne çıkmaktadır. Protein ve yağ yıkımıyla karakterize olan kaşeksi durumunda ise enzim replasmanı ve beslenme desteği hayati rol oynar. Ayrıca, yüksek risk teşkil eden tromboemboli ve psikolojik sorunların yönetimi de palyatif sürecin ayrılmaz parçalarıdır. Sonuç olarak, küratif tedavi şansı düşük olan bu hasta grubunda multidisipliner bir yaklaşımla semptom kontrolü sağlanması hedeflenmelidir.
Palliative care in pancreatic cancer is crucial for improving quality of life since 80% of patients are diagnosed at advanced stages, focusing on managing jaundice, gastric outlet obstruction (GOO), severe pain, and cachexia. Obstructive jaundice, prevalent in pancreatic head tumors, is primarily treated via ERCP with plastic or metallic stenting, while surgical drainage is reserved for patients with longer life expectancies. For GOO caused by duodenal invasion, gastrojejunostomy remains the gold standard treatment, though endoscopic metallic stenting offers a less invasive alternative. Pain management, essential due to frequent celiac plexus invasion, involves a step-ladder analgesic approach and celiac nerve blocks, while cachexia is addressed through enzyme replacement and nutritional support. Additionally, managing the high risk of thromboembolism and psychological issues like depression is integral to this process. Ultimately, a multidisciplinary approach is necessary to provide the best possible care through effective symptom control in patients for whom curative treatment is no longer an option.
Referanslar
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30.
Perone JA, Riall TS, Olino K. Palliative Care for Pancreatic and Periampullary Cancer. Surg Clin North Am. 2016 Dec;96(6):1415-1430.
Kılıçturgay S., Sarkut P. Pankreas Tümörlerinde Palyatif Tedavi. Türkiye Klinikleri J Gen Surg-Special Topics 2015;8(4)
Adiwinata R, Livina A, Waleleng BJ. Palliative Management of Advanced Pancreatic Cancer: The Role of Gastroentero-hepatologist. Acta Med Indones. 2020 Apr;52(2):185-191.
Kneuertz PJ, Cunningham SC, Cameron JL. Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience. J Gastrointest Surg. 2011 Nov;15(11):1917-27.
Stark A, Hines OJ. Endoscopic and operative palliation strategies for pancreatic ductal adenocarcinoma. Semin Oncol. 2015 Feb;42(1):163-76.
Huguier M, Baumel H, Manderscheid JC. Surgical palliation for unresected cancer of the exocrine pancreas. Eur J Surg Oncol. 1993;19: 342–7.
Sarfeh IJ, Rypins EB, Jakowatz JG. A prospective, randomized clinical investigation of cholecystoenterostomy and choledochoenterostomy. Am J Surg. 1988;155:411–4.
Dumonceau JM, Tringali A, Blero D. Biliary stenting: indications, choice of stents and results: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline. Endoscopy. 2012;44: 277–98.
Maire F, Sauvanet A. Palliation of biliary and duodenal obstruction in patients with unresectable pancreatic cancer: endoscopy or surgery? J Visc Surg 2013;150(3 Suppl):S27–31.
House MG, Choti MA. Palliative therapy for pancreatic/biliary cancer. Surg Clin North Am 2005;85(2):359–71.
Kneuertz PJ, Cunningham SC, Cameron JL. Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience. J Gastrointest Surg. 2011 Nov;15(11):1917-27.
Nakakura EK, Warren RS. Palliative care for patients with advanced pancreatic and biliary cancers. Surg Oncol. 2007 Dec;16(4):293-7. doi: 10.1016/j.suronc.2007.08.003. Epub 2007 Sep 14. PMID: 17855076.
Navarra G, Musolino C, Venneri A. Palliative antecolic isoperistaltic gastrojejunostomy: a randomized controlled trial comparing open and laparoscopic approaches. Surg Endosc. 2006 Dec;20(12):1831-4.
Lillemoe KD, Cameron JL, Hardacre JM. Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg 1999;230(3):322–8.
Van Heek NT, DeCastro SM, van Eijck CH. The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer: a prospective randomized multicenter trial with special focus on assessment of quality of life. Ann Surg 2003;238(6):894–902.
Gurusamy KS, Kumar S, Davidson BR. Prophylactic gastrojejunostomy for unresectable periampullary carcinoma. Cochrane Database Syst Rev 2013;(2):CD008533.
Rudolph HU, Post S, Schlu¨ter M. Malignant gastroduodenal obstruction: retrospective comparison of endoscopic and surgical palliative therapy. Scand J Gastroenterol 2011;46(5):583–90.
Jeurnink SM, Steyerberg EW, van Hooft JE. Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. Gastrointest Endosc 2010; 71(3):490–9.
Lohse I, Brothers SP. Pathogenesis and Treatment of Pancreatic Cancer Related Pain. Anticancer Res. 2020 Apr;40(4):1789-1796.
Wong GY, Schroeder DR, Carns PE. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 2004; 291(9):1092–9.
Erdek MA, King LM, Ellsworth SG. Pain management and palliative care in pancreatic cancer. Curr Probl Cancer 2013;37(5):266–72.
Fazal S, Saif MW. Supportive and palliative care of pancreatic cancer. JOP 2007; 8(2):240–53.
Uomo G, Gallucci F, Rabitti PG. Anorexiacachexia syndrome in pancreatic cancer: recent development in research and management. JOP 2006;7(2):157-62
Wigmore SJ, Barber MD, Ross JA et al. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 2000;36(2): 177-84
Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol 2004;5(11):655–63.
Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349(2):146–53.
